258 results
ARS
2023 FY
MYGN
Myriad Genetics, Inc.
17 Apr 24
Annual report to shareholders
4:33pm
’ coverage and reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests … on a state-by-state basis, which we expect will result in more growth and adoption of genetic testing by clinicians and acceptance by local reimbursement
8-K
m0lzeih3op2t2jn95y
27 Feb 24
Results of Operations and Financial Condition
4:05pm
8-K
EX-99.1
fpx17wk 5rxcpva
27 Feb 24
Results of Operations and Financial Condition
4:05pm
8-K
EX-99.1
53u3qgk9yv7w60b rr
16 Jan 24
Results of Operations and Financial Condition
9:00am
8-K
uqspcvw
16 Jan 24
Results of Operations and Financial Condition
9:00am
8-K
EX-99.1
9go h8qxisarczwrkr
21 Dec 23
Departure of Directors or Certain Officers
8:30am
424B5
83wzhl
13 Nov 23
Prospectus supplement for primary offering
6:02am
424B5
3dsrizfkqe9
8 Nov 23
Prospectus supplement for primary offering
4:05pm
S-3ASR
x896agww
8 Nov 23
Automatic shelf registration
4:01pm
S-3ASR
EX-4.3
7ed1x3o5y pgb
8 Nov 23
Automatic shelf registration
4:01pm